{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:41:12Z","timestamp":1761061272089,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009858","name":"Gabrielle\u2019s Angel Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bbmt.2020.07.014","type":"journal-article","created":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T19:15:34Z","timestamp":1595099734000},"page":"1811-1818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Rituximab and Host\/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies"],"prefix":"10.1016","volume":"26","author":[{"given":"Noa","family":"Granot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara S.","family":"Pender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry E.","family":"Storer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.07.014_bib0001","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0002","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2004.05194.x","article-title":"Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation","volume":"127","author":"Toze","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry-matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0004","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.1992.10.11.1690","article-title":"Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group registry data","volume":"10","author":"Chopra","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0005","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0006","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2141.1999.01666.x","article-title":"Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle","volume":"107","author":"Dhedin","year":"1999","journal-title":"Br J Haematol."},{"key":"10.1016\/j.bbmt.2020.07.014_bib0007","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2020.07.014_bib0008","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0009","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/bbmt.2002.v8.pm12374456","article-title":"Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study","volume":"8","author":"Junghanss","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0010","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood-2003-05-1597","article-title":"Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation","volume":"102","author":"Fukuda","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0011","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.bbmt.2019.06.025","article-title":"Allogeneic hematopoietic cell transplantation in the outpatient setting","volume":"25","author":"Granot","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0012","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0013","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2141.2008.07365.x","article-title":"Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience","volume":"143","author":"Rezvani","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0014","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc\u03b3RIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0015","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall'Ozzo","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0016","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2005.06.059","article-title":"Polymorphisms in Fc\u03b3RIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstr\u00f6m's macroglobulinemia","volume":"23","author":"Treon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0017","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2006-01-009480","article-title":"FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0018","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3324\/haematol.10327","article-title":"FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma","volume":"92","author":"Mitrovi\u00e7","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0019","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0021","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic Cell Transplantation (HCT)-Specific Comorbidity Index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0022","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1182\/blood.V92.10.3515","article-title":"Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient","volume":"92","author":"Petersdorf","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ajh.25665","article-title":"Phase I\/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia","volume":"95","author":"Krakow","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0024","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"Niederwieser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0025","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbmt.2011.01.017","article-title":"A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells","volume":"17","author":"Inamoto","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0026","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0027","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0028","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0029","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","article-title":"Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0030","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1023\/A:1015463811683","article-title":"Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?","volume":"22","author":"Selenko","year":"2002","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0031","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0032","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1177\/0091270011430506","article-title":"Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia","volume":"52","author":"Li","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0033","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/bcp.13271","article-title":"Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome","volume":"83","author":"Rozman","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0034","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1365-2141.2009.07674.x","article-title":"Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation (PBSCT)","volume":"145","author":"Ratanatharathorn","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0035","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2017.10.011","article-title":"Fludarabine and busulfan versus fludarabine, cyclophosphamide, and rituximab as reduced-intensity conditioning for allogeneic transplantation in follicular lymphoma","volume":"24","author":"Epperla","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0036","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13045-017-0487-y","article-title":"Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma","volume":"10","author":"Epperla","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0037","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0038","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bbmt.2013.11.029","article-title":"A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients","volume":"20","author":"Sauter","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0039","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2011.050419","article-title":"Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone","volume":"97","author":"Persky","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0040","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.bbmt.2015.07.012","article-title":"Phase II study of nonmyeloablative allogeneic bone marrow transplantation for B cell lymphoma with post-transplantation rituximab and donor selection based first on non-HLA factors","volume":"21","author":"Kanakry","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0041","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0042","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0043","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3324\/haematol.11288","article-title":"Fc\u03b3RIIIA and Fc\u03b3RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab","volume":"92","author":"Carlotti","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0044","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1200\/JCO.2004.06.003","article-title":"Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype","volume":"22","author":"Weng","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0045","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1080\/10428190903128660","article-title":"Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma","volume":"50","author":"Weng","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0046","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hon.2305","article-title":"FCGR3A\/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1,134 patients from two prospective cohorts","volume":"35","author":"Ghesqui\u00e8res","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0047","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4274\/Tjh.2013.0367","article-title":"The effect of Fc\u03b3RIIIA gene polymorphism on the treatment of diffuse large B-cell non-Hodgkin lymphoma: a multicenter prospective observational study","volume":"32","author":"B\u00fcy\u00fckkurt","year":"2015","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0048","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2003-07-2548","article-title":"Fc\u03b3RIIIa and Fc\u03b3RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia","volume":"103","author":"Farag","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0049","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2004-09-3660","article-title":"Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission","volume":"105","author":"Miklos","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0050","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1182\/blood-2008-10-161638","article-title":"The role of B cells in the pathogenesis of graft-versus-host disease","volume":"114","author":"Shimabukuro-Vornhagen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0051","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0052","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood-2014-11-613323","article-title":"Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans","volume":"125","author":"Nakasone","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0053","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","article-title":"Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura","volume":"110","author":"Stasi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0054","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1080\/10428194.2018.1543881","article-title":"Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath?","volume":"60","author":"Papalexandri","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0055","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0056","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/10428190601094362","article-title":"Rituximab is effective for extensive steroid-refractory chronic graft-vs-host-disease","volume":"48","author":"Carella","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.07.014_bib0057","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.bmt.1705725","article-title":"Treatment of refractory chronic GVHD with rituximab: a GITMO study","volume":"40","author":"Zaja","year":"2007","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:13:26Z","timestamp":1761059606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120304456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1083879120304456"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.014","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Rituximab and Host\/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}